TY - JOUR
T1 - Technical recommendations for clinical translation of renal MRI
T2 - a consensus project of the Cooperation in Science and Technology Action PARENCHIMA
AU - Mendichovszky, Iosif
AU - Pullens, Pim
AU - Dekkers, Ilona
AU - Nery, Fabio
AU - Bane, Octavia
AU - Pohlmann, Andreas
AU - de Boer, Anneloes
AU - Ljimani, Alexandra
AU - Odudu, Aghogho
AU - Buchanan, Charlotte
AU - Sharma, Kanishka
AU - Laustsen, Christoffer
AU - Harteveld, Anita
AU - Golay, Xavier
AU - Pedrosa, Ivan
AU - Alsop, David
AU - Fain, Sean
AU - Caroli, Anna
AU - Prasad, Pottumarthi
AU - Francis, Susan
AU - Sigmund, Eric
AU - Fernández‐Seara, Maria
AU - Sourbron, Steven
N1 - Funding Information:
The subject matter falls under the remit of the Quantitative Imaging Biomarkers Alliance (QIBA) of the Radiological Society of North America (RSNA), but QIBA has adopted a different evidence-based approach to support the development and confirmation of profiles focused on specific biomarkers. This is opposed to the more general recommendations here, which focus on multiple contrast mechanisms and biomarkers within four renal MRI modalities. Nevertheless, specific biomarkers that emerge from the PARENCHIMA process could potentially be advanced using the QIBA approach. Another consortium funded by the NIH, the Quantitative Imaging Network (QIN), supports development of quantitative imaging tools for the particular application of predicting tumour response to therapy, and also enshrines core values of standardisation, repeatability, and wide translation. Should the PARENCHIMA effort expand towards oncology (renal masses), some collaboration with QIN could be considered.
Funding Information:
XG is partly supported by The National Institute of Health Research (NIHR) Biomedical Research Centre; AP receives funding from the German Research Council (DFG; Collaborative Research Centre SFB 1365 Renoprotection); AH received funding from the Netherlands Organization for Scientific Research (14951); SS and KS received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. STF, SS and IAM receive funding from the Medical Research Council (Grant Number MR/R02264X/1); MAFS received funding from the Spanish Ministry of Economy and Competitiveness (IEDI-2017-00826); FN funding from Great Ormond Street Hospital Children’s Charity (V0318), and Medical Research Council (MR/R02264x/1); CL received funding from Aarhus university foundation and Karen Elise Jensen’s Foundation; AB was supported by an Alexandre Suerman stipend for M.D.–Ph.D. students granted by the University Medical Center Utrecht, The Netherlands; OB Grant support (2016–2018) from National Institute of Health (NIH) NIDDK individual fellowship 1F32DK109591. IP received funding from the NIH National Cancer Institute (Grants RO1CA154475, P50CA196516, and U01CA20709). Acknowledgements
Funding Information:
This article is based upon work from the COST Action CA16103 Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease (PARENCHIMA), funded by COST (European Cooperation in Science and Technology). For additional information, please visit PARENCHIMA project website: www.renalmri.org .
Publisher Copyright:
© 2019, The Author(s).
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Purpose: The potential of renal MRI biomarkers has been increasingly recognised, but clinical translation requires more standardisation. The PARENCHIMA consensus project aims to develop and apply a process for generating technical recommendations on renal MRI. Methods: A task force was formed in July 2018 focused on five methods. A draft process for attaining consensus was distributed publicly for consultation and finalised at an open meeting (Prague, October 2018). Four expert panels completed surveys between October 2018 and March 2019, discussed results and refined the surveys at a face-to-face meeting (Aarhus, March 2019) and completed a second round (May 2019). Results: A seven-stage process was defined: (1) formation of expert panels; (2) definition of the context of use; (3) literature review; (4) collection and comparison of MRI protocols; (5) consensus generation by an approximate Delphi method; (6) reporting of results in vendor-neutral and vendor-specific terms; (7) ongoing review and updating. Application of the process resulted in 166 consensus statements. Conclusion: The process generated meaningful technical recommendations across very different MRI methods, while allowing for improvement and refinement as open issues are resolved. The results are likely to be widely supported by the renal MRI community and thereby promote more harmonisation.
AB - Purpose: The potential of renal MRI biomarkers has been increasingly recognised, but clinical translation requires more standardisation. The PARENCHIMA consensus project aims to develop and apply a process for generating technical recommendations on renal MRI. Methods: A task force was formed in July 2018 focused on five methods. A draft process for attaining consensus was distributed publicly for consultation and finalised at an open meeting (Prague, October 2018). Four expert panels completed surveys between October 2018 and March 2019, discussed results and refined the surveys at a face-to-face meeting (Aarhus, March 2019) and completed a second round (May 2019). Results: A seven-stage process was defined: (1) formation of expert panels; (2) definition of the context of use; (3) literature review; (4) collection and comparison of MRI protocols; (5) consensus generation by an approximate Delphi method; (6) reporting of results in vendor-neutral and vendor-specific terms; (7) ongoing review and updating. Application of the process resulted in 166 consensus statements. Conclusion: The process generated meaningful technical recommendations across very different MRI methods, while allowing for improvement and refinement as open issues are resolved. The results are likely to be widely supported by the renal MRI community and thereby promote more harmonisation.
KW - Biomarkers
KW - Consensus
KW - Imaging
KW - Kidney
KW - Standardisation
UR - http://www.scopus.com/inward/record.url?scp=85074470136&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074470136&partnerID=8YFLogxK
U2 - 10.1007/s10334-019-00784-w
DO - 10.1007/s10334-019-00784-w
M3 - Article
C2 - 31628564
AN - SCOPUS:85074470136
SN - 1352-8661
VL - 33
SP - 131
EP - 140
JO - Magnetic Resonance Materials in Physics, Biology, and Medicine
JF - Magnetic Resonance Materials in Physics, Biology, and Medicine
IS - 1
ER -